| dc.description | Bismuth compounds have demonstrated bioactivity for over two hundred years. The most obvious exploitation is the widespread use of bismuth pharmaceuticals, namely, Pepto-Bismol and De-Nol in the treatment of peptic ulcer disease. However, the mechanism of bioactivity for bismuth compounds remains unknown and enhancement and development of their utility requires a fundamental understanding of the bismuth chemistry involved. An effective approach is the rational synthesis of systematic series of structurally simple bismuth(III) compounds. General, high yield metathesis reactions provide three related and comprehensive series of dithia and oxathiabismuth heterocycles, (1), (2) and (3) (X = Cl, Br, I, SCH $\rm CH\sb2CH\sb2OH;\ R = (CH\sb2)\sb{2-4},\ (CH\sb2)\sb2O(CH\sb2),\ (CH\sb2)S(CH\sb2)\sb2,$ Y = Cl, Br, I, $\rm NO\sb3,\ CH\sb3COO).$ The thermodynamic preference for bismuth to adopt five-membered rings is demonstrated in the structures of dithiabismolane derivatives (X = Cl, Br, I, $\rm S(CH\sb2)\sb2OH)$ and the bicyclic bis-(2-hydroxylethanethiolato)bismuth compounds. The compounds are characterized by vibrational and mass spectroscopic, and X-ray crystal analysis. The solid state structures of (3) show a flexible framework which is attributed to the relative donor capabilities of the anions.(DIAGRAM, TABLE OR GRAPHIC OMITTED...PLEASE SEE DAI) | en_US |
